Trial Profile
Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Congenital heart defects
- Focus Pharmacokinetics
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.
- 14 Nov 2018 Results developing a population PK model by taking data from this trial, presented at the 91st Annual Scientific Sessions of the American Heart Association.
- 09 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.